ERBB2 and breast carcinoma: Multiple pre-clinical investigations showed efficacy of NK-CAR cells targeting HER2 in HER2+ breast cancer (109, 110), tissue-factor in TNBC (111), epithelial cell adhesion molecule (EpCAM) in both HER2+ and TNBC (112) and epidermal growth factor (EGFR) in all breast cancer subtypes (113).